Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical Dilemmas in the Treatment of Elderly Patients Suffering from Hodgkin Lymphoma: A Review.
Milunović V, Hude I, Rinčić G, Galušić D, Grubešić A, Martinović M, Popović N, Divošević S, Brčić K, Međugorac M, Kužat L, Strahija D, Mrđenović S, Mandac Smoljanović I, Radić-Krišto D, Gašparov S, Aurer I, Ostojić Kolonić S. Milunović V, et al. Among authors: galusic d. Biomedicines. 2022 Nov 14;10(11):2917. doi: 10.3390/biomedicines10112917. Biomedicines. 2022. PMID: 36428485 Free PMC article. Review.
Efficacy and Safety of Obinutuzumab-chemotherapy Combinations in Front-line Treatment of Follicular Non-Hodgkin Lymphoma During the COVID-19 Pandemic: A Study of KROHEM, the Croatian Cooperative Group for Hematologic Diseases.
Galusic D, Basic-Kinda S, Pijuk A, Milunovic V, Dreta B, Franjic N, Coha B, Sincic-Petricevic J, Gacina P, Pejsa V, Lucijanic M, Aurer I. Galusic D, et al. Hemasphere. 2022 Nov 15;6(12):e807. doi: 10.1097/HS9.0000000000000807. eCollection 2022 Dec. Hemasphere. 2022. PMID: 36407092 Free PMC article.
Dose-adjusted EPOCH and rituximab (DA-EPOCH-R) in older patients with high-risk aggressive diffuse large B-cell lymphoma: A real-life multicenter study by the Croatian Cooperative Group for Hematologic diseases (KroHem).
Mitrovic Z, Dujmovic D, Jaksic O, Kinda SB, Gacina P, Perisa V, Prka Z, Dreta B, Galusic D, Holik H, Pejsa V, Aurer I. Mitrovic Z, et al. Among authors: galusic d. Eur J Haematol. 2023 Jun;110(6):725-731. doi: 10.1111/ejh.13957. Epub 2023 Apr 2. Eur J Haematol. 2023. PMID: 36941738
Clinical presentation, treatment patterns, and outcomes of pulmonary embolism in patients with chronic myeloproliferative neoplasms.
Krečak I, Grohovac D, Vučenović Bašić N, Čeko M, Nižetić K, Sabljić A, Holik H, Galušić D, Zekanović I, Morić Perić M, Periša V, Lucijanić M. Krečak I, et al. Among authors: galusic d. Thromb Res. 2023 Nov;231:141-143. doi: 10.1016/j.thromres.2023.03.004. Epub 2023 Mar 21. Thromb Res. 2023. PMID: 36964024 No abstract available.
Ruxolitinib treatment improves muscle mass in patients with myelofibrosis.
Lucijanic M, Galusic D, Soric E, Sedinic M, Cubela M, Huzjan Korunic R, Pejsa V, Kusec R. Lucijanic M, et al. Among authors: galusic d. Ann Hematol. 2021 Apr;100(4):1105-1106. doi: 10.1007/s00277-020-04243-8. Epub 2020 Sep 1. Ann Hematol. 2021. PMID: 32870367 No abstract available.
[No title available]
[No authors listed] [No authors listed] PMID: 36164017
21 results